ZNTL
HEALTHCAREZentalis Pharmaceuticals Inc
$4.18+0.09 (+2.20%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ZNTL Today?
No stock-specific AI insight has been generated for ZNTL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.13$6.95
$4.18
Fundamentals
Market Cap$298M
P/E Ratio—
EPS$-1.91
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume834K
Avg Volume (10D)—
Shares Outstanding71.2M
ZNTL News
20 articles- Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerYahoo Finance·May 5, 2026
- Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·May 1, 2026
- Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerYahoo Finance·Apr 21, 2026
- Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetYahoo Finance·Apr 20, 2026
- Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026Yahoo Finance·Apr 17, 2026
- A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection MilestoneYahoo Finance·Apr 13, 2026
- Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerYahoo Finance·Apr 9, 2026
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 1, 2026
- Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesYahoo Finance·Mar 26, 2026
- Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026Yahoo Finance·Mar 17, 2026
- Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 18, 2026
- Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming SoonMarketbeat·Feb 16, 2026
- Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferenceYahoo Finance·Feb 3, 2026
- Mitsui Sumitomo Continues to Build WR Berkley Stake247 Wall St·Jan 13, 2026
- A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider BuyingYahoo Finance·Jan 11, 2026
- Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional ownersYahoo Finance·Jan 8, 2026
- Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026Yahoo Finance·Jan 6, 2026
- We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn RateYahoo Finance·Dec 3, 2025
- Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational ProgressYahoo Finance·Nov 10, 2025
- Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 13, 2025
All 20 articles loaded
Price Data
Open$4.14
Previous Close$4.09
Day High$4.20
Day Low$3.90
52 Week High$6.95
52 Week Low$1.13
52-Week Range
$1.13$6.95
$4.18
Fundamentals
Market Cap$298M
P/E Ratio—
EPS$-1.91
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume834K
Avg Volume (10D)—
Shares Outstanding71.2M
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—